Stocks in play: Zenith Epigenetics Ltd.

Announced today the dosing of first patient with a triple combination of ZEN-3694 + Merck’s immune check point inhibitor, KEYTRUDA, + Pfizer’s androgen receptor signaling inhibitor (ARSI), XTANDI, in a University of California, San Francisco (UCSF) investigator led metastatic castration resistant prostate cancer (mCRPC) Phase 2 clinical trial. ZEN-3694, the Company’s lead therapeutic compound, is being developed for epigenetic combination therapies in multiple oncology indications. Zenith Epigenetics Ltd. shares T.RVX are trading up $0.16 at $1.05.

Read:

• Growth in China: Digital Marketing Spending Expected to Increase 20% This Year

• One of the Top Gold Bulls is Calling for the Metal to Hit $15000